Source: Pharmacy Times articles
Sundar Jagannath, MD, discusses how prophylactic tocilizumab reduced cytokine release syndrome incidence and severity with talquetamab in relapsed or refractory (R/R) multiple myeloma.
Recent Content
- FDA grants orphan drug status to new treatment for agressive blood cancers
- FDA gives green light to first human trial testing cancer drug GTB-5550
- Tumour-intrinsic features shape T cell differentiation through precursor to symptomatic multiple myeloma
- (no title)
- (no title)
- Scientists test treatment strategy using ‘glioblastoma on a chip’
- (no title)
- (no title)
- (no title)
- Prostate cancer tool may cut risk for women in radiation therapy